Abstract
Background Hodgkin lymphoma (HL) has come a long way from being a disease with high mortality to being highly curable, which thereby exposes survivors to the potential for long-term toxicities. Our aim was to analyze the National Cancer Data Base for trends in radiation therapy use among all stages of HL from 2000 to 2012 and to see if increased recognition of these risks has decreased the use of radiation therapy. Patients and Methods This was a retrospective study of patients diagnosed with HL (stage I-IV) between the years 2000 and 2012 using the National Cancer Data Base (n = 24,118). The National Cancer Data Base is a nationwide oncology outcomes database for more than 1500 American College of Surgeons Commission on Cancer accredited cancer programs. The study focused on the proportion of patients who received radiation therapy. Results Between the years 2000 and 2012, use of radiation therapy declined among all stages of HL (stage I: 53% to 40%, P =.0002; stage II: 52% to 36%, P
| Original language | English |
|---|---|
| Pages (from-to) | 12-17 |
| Number of pages | 6 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cancer Research
- Hematology
- Oncology
Cite this
Trends in Use of Radiation Therapy for Hodgkin Lymphoma from 2000 to 2012 on the Basis of the National Cancer Data Base. / Goyal, Gaurav; Silberstein, Peter T.; Armitage, James O.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 16, No. 1, 01.01.2016, p. 12-17.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trends in Use of Radiation Therapy for Hodgkin Lymphoma from 2000 to 2012 on the Basis of the National Cancer Data Base
AU - Goyal, Gaurav
AU - Silberstein, Peter T.
AU - Armitage, James O.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background Hodgkin lymphoma (HL) has come a long way from being a disease with high mortality to being highly curable, which thereby exposes survivors to the potential for long-term toxicities. Our aim was to analyze the National Cancer Data Base for trends in radiation therapy use among all stages of HL from 2000 to 2012 and to see if increased recognition of these risks has decreased the use of radiation therapy. Patients and Methods This was a retrospective study of patients diagnosed with HL (stage I-IV) between the years 2000 and 2012 using the National Cancer Data Base (n = 24,118). The National Cancer Data Base is a nationwide oncology outcomes database for more than 1500 American College of Surgeons Commission on Cancer accredited cancer programs. The study focused on the proportion of patients who received radiation therapy. Results Between the years 2000 and 2012, use of radiation therapy declined among all stages of HL (stage I: 53% to 40%, P =.0002; stage II: 52% to 36%, P
AB - Background Hodgkin lymphoma (HL) has come a long way from being a disease with high mortality to being highly curable, which thereby exposes survivors to the potential for long-term toxicities. Our aim was to analyze the National Cancer Data Base for trends in radiation therapy use among all stages of HL from 2000 to 2012 and to see if increased recognition of these risks has decreased the use of radiation therapy. Patients and Methods This was a retrospective study of patients diagnosed with HL (stage I-IV) between the years 2000 and 2012 using the National Cancer Data Base (n = 24,118). The National Cancer Data Base is a nationwide oncology outcomes database for more than 1500 American College of Surgeons Commission on Cancer accredited cancer programs. The study focused on the proportion of patients who received radiation therapy. Results Between the years 2000 and 2012, use of radiation therapy declined among all stages of HL (stage I: 53% to 40%, P =.0002; stage II: 52% to 36%, P
UR - http://www.scopus.com/inward/record.url?scp=84952876261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952876261&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2015.11.006
DO - 10.1016/j.clml.2015.11.006
M3 - Article
VL - 16
SP - 12
EP - 17
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2669
IS - 1
ER -